Aurobindo Pharma Q3 FY26: Strategic Growth Amidst Market Dynamics

Aurobindo Pharma Limited has reported a robust performance for the third quarter of fiscal year 2026 (Q3 FY26), demonstrating sustained business momentum and strategic execution across its global operations. The company's consolidated revenue from operations surged by 8.4% year-on-year, reaching an impressive ₹8,646 crores. This growth was primarily fueled by exceptional performance in Europe and a stable contribution from the US market, even amidst lower transient product sales. The company's EBITDA also saw a healthy increase of 9% year-on-year, totaling ₹1,773 crores, with a strong margin of 20.5%. This reflects effective operating efficiencies and stable gross margins, underscoring the company's fiscal prudence and consistent strategy execution. Profit after tax (PAT) for the quarter stood at ₹910 crores, marking a 7.6% increase over the previous year.

The overall formulation business was a key driver, recording a 10% year-on-year growth to ₹7,683 crores, contributing approximately 89% of the total consolidated revenue. Europe emerged as a standout performer, delivering a remarkable 27.4% year-on-year revenue growth to ₹2,703 crores (261 million Euros). This strong momentum across key European markets positions Aurobindo to exceed 1 billion Euros in annual European revenue by the close of FY26. The US formulations business, excluding gRevlimid, remained stable, with injectable sales growing by 17% year-on-year. During the quarter, the company successfully launched 9 new products and received approval for 7 ANDAs in the US, reflecting a robust pipeline performance. In contrast, the API business experienced a 4.3% year-on-year decline, with revenues at ₹963 crores, primarily impacted by prevailing market conditions. Growth Markets also saw a marginal decrease of 0.9% year-on-year, influenced by a slight decline in Indonesia, offset by growth in other key markets.

Strategic Initiatives and Future Outlook

Aurobindo Pharma is actively pursuing several strategic initiatives to bolster its long-term growth trajectory. The company's biosimilars division, CuraTeQ Biologics, is making significant strides, with recent approvals and launches in Europe, including Bevqolva in the UK and Dazublys in Lithuania. CuraTeQ is advancing a robust pipeline of 15 biosimilars across oncology and immunology, targeting a substantial addressable market estimated to exceed $50 billion by 2032. Key filings for BP16 (denosumab biosimilar) and BP11 (omalizumab biosimilar) are planned for 2026, with pre-submission meetings for a bevacizumab biosimilar filing targeted for Q2/Q3 CY2026. This proactive approach underscores Aurobindo's commitment to becoming a global biosimilars player.

Another pivotal development is the ramp-up of the Pen-G manufacturing facility. This facility has already achieved break-even and is now contributing to profitability. Production is steadily increasing, with an annualised capacity expected to exceed 10,000 metric tonnes within the next 12 months. The Government of India's recent notification introducing a one-year CIF on minimum import price for Pen-G, 6APA, and Amoxicillin is a significant positive catalyst, expected to enhance cost competitiveness and strengthen margins from Q1 FY27. This initiative is crucial for India's self-reliance in antibiotics and reducing supply disruption risks.

Operational Excellence and Capital Allocation

The company's focus on operational excellence extends to its manufacturing footprint. The Dayton facility has successfully transitioned into a commercial phase, with manufacturing underway and expected to contribute significantly to revenues from FY27. The proposed acquisition of Lannett Company LLC by Aurobindo Pharma USA Inc. is also on track, with completion anticipated in Q1 FY27, which is expected to further strengthen the US business through synergies. Furthermore, Aurobindo is making a strategic investment of ₹66 crores to acquire up to a 26% stake in Garuda Renewables Private Limited. This investment aims to procure renewable energy from hybrid wind and solar sources, leading to substantial savings in power costs, a lower initial outlay, and an improved ESG profile through reduced carbon emissions.

Management emphasized disciplined capital allocation, focusing on strategic inorganic growth opportunities and biologics-related capital expenditure, rather than major greenfield projects. The company generated $118 million in free cash flows during the quarter, resulting in a strong net cash position of approximately$251 million (including investments) as of December 31, 2025, after appropriating cash for the Khandelwal Labs acquisition. This robust liquidity position provides flexibility for future strategic initiatives.

Concluding Thoughts

Aurobindo Pharma's Q3 FY26 results reflect a company in a strong growth phase, driven by strategic initiatives and operational efficiencies. Despite some headwinds in the API and Growth Markets segments, the robust performance in Europe and the stable US market, coupled with advancements in biosimilars and the Pen-G project, paint a positive picture. The management's confidence in achieving an EBITDA margin target of 20-21% for FY26, along with a clear roadmap for key projects, reinforces its commitment to sustained long-term value creation. The company's diversified operating model, expanding manufacturing footprint, and strategic acquisitions position it well to capitalize on rising demand and improve operating leverage in the coming years.